Lopez April, Long Charron, Happe Laura E, Relish Michael
500 W Main St, Louisville, KY 40202. E-mail:
Am J Manag Care. 2015 Nov 1;21(11):e601-8.
To investigate exposure sequences correlated with gaps in diabetes medication refills and to identify opportunities for targeted outreach for improved adherence.
Sequence discovery was used to identify exposures from various data sources that preceded a gap in diabetes medication refills.
Patients who refilled a diabetes medication and had 6 months of continuous refill history were included. Patients with a therapy gap between February 1, 2012, and March 31, 2013, formed the gap group; those without formed the no-gap group. Gaps were defined as a prescription refill obtained 6 days or more after the days' supply of the previous refill. Exposure sequences were explored in the 90 days before the gap, or before the date of last refill in the study period for the no-gap group. Exposures and sequences offering opportunity for health plan outreach were identified based on sequence length, confidence, number of intervention points, and higher gap group prevalence.
Three exposure sequences with the greatest outreach opportunity to impact downstream adherence were identified within individuals taking diabetes medications who: 1) are prescribed a new medication-especially those with multiple out-of-network claims and/or visit a specialty physician after the new medication is prescribed; 2) have a prescription claim reversed by a pharmacist-particularly patients who are subsequently prescribed a new medication or visit a specialty physician; and 3) have multiple out-of-network claims and a hospitalization.
As medication adherence is a persisting challenge, novel application of sequence discovery techniques identified unique sequences of events with opportunities for outreach.
调查与糖尿病药物续方中断相关的暴露序列,并确定进行有针对性的外展干预以提高依从性的机会。
采用序列发现法,从各种数据源中识别出糖尿病药物续方中断之前的暴露因素。
纳入有糖尿病药物续方记录且有6个月连续续方史的患者。2012年2月1日至2013年3月31日期间存在治疗中断的患者组成中断组;无治疗中断的患者组成无中断组。中断定义为在前一次续方的用药天数供应结束6天或更长时间后才进行的处方续方。在中断前90天内,或在无中断组研究期间的最后一次续方日期之前,探索暴露序列。根据序列长度、可信度、干预点数量以及中断组更高的患病率,确定有机会进行健康计划外展干预的暴露因素和序列。
在服用糖尿病药物的个体中,确定了三个对下游依从性影响最大且具有最大外展干预机会的暴露序列:1)被开具新药——尤其是那些有多次网络外理赔和/或在开具新药后就诊于专科医生的患者;2)药剂师撤销处方——特别是那些随后被开具新药或就诊于专科医生的患者;3)有多次网络外理赔和一次住院治疗。
由于药物依从性仍然是一个挑战,序列发现技术的新应用识别出了具有外展干预机会的独特事件序列。